- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Journal of Oncology
Volume 2013 (2013), Article ID 183602, 6 pages
Multiple Myeloma Macrophages: Pivotal Players in the Tumor Microenvironment
Department of Biomedical Sciences and Human Oncology, Clinica Medica “G. Baccelli,” University of Bari Aldo Moro Medical School, Piazza Giulio Cesare 11, 1-70124 Bari, Italy
Received 4 October 2012; Accepted 3 January 2013
Academic Editor: Rathindranath Baral
Copyright © 2013 Simona Berardi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- N. G. Kastrinakis, V. G. Gorgoulis, P. G. Foukas, M. A. Dimopoulos, and C. Kittas, “Molecular aspects of multiple myeloma,” Annals of Oncology, vol. 11, no. 10, pp. 1217–1228, 2000.
- M. J. Bissell and W. C. Hines, “Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression,” Nature Medicine, vol. 17, no. 3, pp. 320–329, 2011.
- W. S. Dalton, L. Hazlehurst, K. Shain, T. Landowski, and M. Alsina, “Targeting the bone marrow microenvironment in hematologic malignancies,” Seminars in Hematology, vol. 41, no. 2, supplement 4, pp. 1–5, 2004.
- R. A. Kyle and S. V. Rajkumar, “Multiple myeloma,” The New England Journal of Medicine, vol. 351, no. 18, pp. 1860–1873, 2004.
- W. S. Dalton, “The tumor microenvironment: focus on myeloma,” Cancer Treatment Reviews, vol. 29, supplement 1, pp. 11–19, 2003.
- L. M. Coussens and Z. Werb, “Inflammation and cancer,” Nature, vol. 420, no. 6917, pp. 860–867, 2002.
- J. W. Pollard, “Tumour-educated macrophages promote tumour progression and metastasis,” Nature Reviews Cancer, vol. 4, no. 1, pp. 71–78, 2004.
- C. Scavelli, B. Nico, T. Cirulli et al., “Vasculogenic mimicry by bone marrow macrophages in patients with multiple myeloma,” Oncogene, vol. 27, no. 5, pp. 663–674, 2008.
- R. L. Gendron, F. Y. Tsai, H. Paradis, and R. J. Arceci, “Induction of embryonic vasculogenesis by bFGF and LIF in vitro and in vivo,” Developmental Biology, vol. 177, no. 1, pp. 332–346, 1996.
- F. O. Martinez, L. Helming, and S. Gordon, “Alternative activation of macrophages: an immunologic functional perspective,” Annual Review of Immunology, vol. 27, pp. 451–483, 2009.
- A. Mantovani, A. Sica, and M. Locati, “New vistas on macrophage differentiation and activation,” European Journal of Immunology, vol. 37, no. 1, pp. 14–16, 2007.
- A. Mantovani, A. Sica, S. Sozzani, P. Allavena, A. Vecchi, and M. Locati, “The chemokine system in diverse forms of macrophage activation and polarization,” Trends in Immunology, vol. 25, no. 12, pp. 677–686, 2004.
- J. Condeelis and J. W. Pollard, “Macrophages: obligate partners for tumor cell migration, invasion, and metastasis,” Cell, vol. 124, no. 2, pp. 263–266, 2006.
- A. Mantovani, P. Allavena, and A. Sica, “Tumour-associated macrophages as a prototypic type II polarised phagocyte population: role in tumour progression,” European Journal of Cancer, vol. 40, no. 11, pp. 1660–1667, 2004.
- C. D. Mills, K. Kincaid, J. M. Alt, M. J. Heilman, and A. M. Hill, “M-1/M-2 macrophages and the Th1/Th2 paradigm,” Journal of Immunology, vol. 164, no. 12, pp. 6166–6173, 2000.
- D. Ribatti, B. Nico, and A. Vacca, “Importance of the bone marrow microenvironment in inducing the angiogenic response in multiple myeloma,” Oncogene, vol. 25, no. 31, pp. 4257–4266, 2006.
- D. C. Jenkins, I. G. Charles, L. L. Thomsen, et al., “Roles of nitric oxide in tumor growth,” Proceedings of the National Academy of Sciences of the United States of America, vol. 92, no. 10, pp. 4392–4396, 1995.
- A. Vacca, D. Ribatti, M. Presta et al., “Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma,” Blood, vol. 93, no. 9, pp. 3064–3073, 1999.
- F. Di Raimondo, M. P. Azzaro, G. A. Palumbo et al., “Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood,” Haematologica, vol. 85, no. 8, pp. 800–805, 2000.
- Y. Zheng, Z. Cai, S. Wang et al., “Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis,” Blood, vol. 114, no. 17, pp. 3625–3628, 2009.
- J. Kim, R. A. Denu, B. A. Dollar, et al., “Macrophages and mesenchymal stromal cells support survival and proliferation of multiple myeloma cells,” British Journal of Haematology, vol. 158, no. 3, pp. 336–346, 2012.
- Z. J. Gu, V. Costes, Z. Y. Lu, et al., “Interleukin-10 is a growth factor for human myeloma cells by induction of an oncostatin M autocrine loop,” Blood, vol. 88, no. 10, pp. 3972–3986, 1996.
- S. Li, X. Zhang, and X. Xia, “Regression of tumor growth and induction of long-term antitumor memory by interleukin 12 electro-gene therapy,” Journal of the National Cancer Institute, vol. 94, no. 10, pp. 762–768, 2002.
- A. M. Roccaro, T. Hideshima, N. Raje et al., “Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells,” Cancer Research, vol. 66, no. 1, pp. 184–191, 2006.
- H. Mayer, H. Bertram, W. Lindenmaier, T. Korff, H. Weber, and H. Weich, “Vascular endothelial growth factor (VEGF-A) expression in human mesenchymal stem cells: autocrine and paracrine role on osteoblastic and endothelial differentiation,” Journal of Cellular Biochemistry, vol. 95, no. 4, pp. 827–839, 2005.
- J. P. Laurila, L. Laatikainen, M. D. Castellone et al., “Human embryonic stem cell-derived mesenchymal stromal cell transplantation in a rat hind limb injury model,” Cytotherapy, vol. 11, no. 6, pp. 726–737, 2009.
- A. Vacca, R. Ria, F. Semeraro, et al., “Endothelial cells in the bone marrow of patients with multiple myeloma,” Blood, vol. 102, no. 9, pp. 3340–3348, 2003.
- M. Anghelina, L. Moldovan, T. Zabuawala, M. C. Ostrowski, and N. I. Moldovan, “A subpopulation of peritoneal macrophages form capillary-like lumens and branching patterns in vitro,” Journal of Cellular and Molecular Medicine, vol. 10, no. 3, pp. 708–715, 2006.
- S. Kumar, T. E. Witzig, M. Timm et al., “Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: evidence favoring loss of marrow angiogenesis inhibitory activity with disease progression,” Blood, vol. 104, no. 4, pp. 1159–1165, 2004.
- N. I. Moldovan, “Functional adaptation: the key to plasticity of cardiovascular “stem” cells?” Stem Cells and Development, vol. 14, no. 2, pp. 111–121, 2005.
- B. Barleon, S. Sozzani, D. Zhou, H. A. Weich, A. Mantovani, and D. Marmé, “Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1,” Blood, vol. 87, no. 8, pp. 3336–3343, 1996.
- G. H. Fong, J. Rossant, M. Gertsenstein, and M. L. Breitman, “Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium,” Nature, vol. 376, no. 6535, pp. 66–70, 1995.
- F. Shalaby, J. Ho, W. L. Stanford et al., “A requirement for Flk1 in primitive and definitive hematopoiesis and vasculogenesis,” Cell, vol. 89, no. 6, pp. 981–990, 1997.
- C. D. Baroni, D. Vitolo, D. Remotti et al., “Immunohistochemical heterogeneity of macrophage subpopulations in human lymphoid tissues,” Histopathology, vol. 11, no. 10, pp. 1029–1042, 1987.
- A. J. Maniotis, R. Folberg, A. Hess et al., “Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry,” American Journal of Pathology, vol. 155, no. 3, pp. 739–752, 1999.
- A. Ben-Baruch, “Inflammation-associated immune suppression in cancer: the roles played by cytokines, chemokines and additional mediators,” Seminars in Cancer Biology, vol. 16, no. 1, pp. 38–52, 2006.
- M. K. Brimnes, A. J. Vangsted, L. M. Knudsen et al., “Increased level of both CD4+FOXP3+ Regulatory t Cells and CD14+HLA-DR−/low myeloid-derived suppressor cells and decreased level of dendritic cells in patients with multiple myeloma,” Scandinavian Journal of Immunology, vol. 72, no. 6, pp. 540–547, 2010.
- D. I. Gabrilovich and S. Nagaraj, “Myeloid-derived suppressor cells as regulators of the immune system,” Nature Reviews Immunology, vol. 9, no. 3, pp. 162–174, 2009.
- P. Serafini, K. Meckel, M. Kelso et al., “Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function,” Journal of Experimental Medicine, vol. 203, no. 12, pp. 2691–2702, 2006.
- J. Epstein and S. Yaccoby, “Consequences of interactions between the bone marrow stroma and myeloma,” The Hematology Journal, vol. 4, no. 5, pp. 310–314, 2003.